204 GSK Annual Report 2017 Notes to the financial statements continued 35.
Related party transactions At 31 December 2017, GSK owned 32 million shares or 31.4% of Innoviva Inc. which is a biopharmaceutical company listed on NASDAQ.
GSK began recognising Innoviva as an associate on 1 September 2015.
The royalties due from GSK to Innoviva in the year were 173 million 2016 108 million.
At 31 December 2017, the balance payable by GSK to Innoviva was 53 million 2016 36 million.
At 31 December 2017, GSK held a 50% interest in Japan Vaccine Co. Ltd JVC through its subsidiary GlaxoSmithKline K. K. This joint venture with Daiichi Sankyo Co. Ltd is primarily responsible for the development and marketing of certain prophylactic vaccines in Japan.
During 2017, GSK sold 41 million 2016 43 million of its vaccine products into the joint venture.
At 31 December 2017, the trading balance due to GSK from JVC was 11 million 2016 9 million and the balance payable by GSK to JVC was nil million 2016 nil.
Loans of 7 million to JVC, 7 million to Medicxi Ventures I LP and 8 million to Index Ventures Life VI Jersey LP remained due to GSK at 31 December 2017.
The aggregate compensation of the Directors and CET is given in Note 9, Employee costs.
Adjustments reconciling profit after tax to operating cash flows 2017 2016 2015 m m m Profit after tax 2,169 1,062 8,372 Tax on profits 1,356 877 2,154 Share of after tax profits of associates and joint ventures 13 5 14 Finance expense net of finance income 669 664 653 Depreciation 988 978 892 Amortisation of intangible assets 934 796 738 Impairment and assets written off 1,061 226 822 Profit on sale of businesses 157 5 9,308 Profit on sale of intangible assets 46 178 349 Profit on sale of investments in associates 94 843 Profit on sale of equity investments 37 254 342 Changes in working capital: Increase decrease in inventories 461 70 111 Increase decrease in trade receivables 287 188 98 Increase in trade payables 11 96 40 Decrease increase in other receivables 74 381 593 Contingent consideration paid see Note 39 594 358 121 Other non-cash increase in contingent consideration liabilities 961 2,281 1,986 Increase in other payables 1,741 1,989 276 Decrease increase in pension and other provisions 255 621 100 Share-based incentive plans 333 319 368 Fair value adjustments 3 Other 95 21 187 6,089 7,044 3,741 Cash generated from operations 8,258 8,106 4,631
